Geert-Jan is one of the co-founding Managing Partners at Forbion and led the firm’s investments of several portfolio companies like bluebird bio, (IPO on Nasdaq 2013), Acorda (IPO on Nasdaq 2006), PanGenetics (sold to Abbott in 2009), Transave (reverse-merger into Insmed in 2010), Exosome Diagnostics (sold to Bio-Techne in 2018), Promedior (sold to Roche in 2020), KaNDy Therapeutics (sold to Bayer in 2020), the sale of the TMEM-16 program by Enterprise Therapeutics (sold to Roche in 2020), Sanifit (sold to Vifor in 2021) and Mariana (sold to Novartis in 2024).